Alexion ALXN Pharmaceuticals rallied with the broad market Thursday and is now 2% past a 118.39 buy point. It’s in buying range, but the breakout has had a hard time getting going, which isn’t the best of signs. After the Oct. 25 breakout, Alexion erased a 7% gain but found its footing at the 50-day line. Alexion’s base was irregular until the Oct. 22 intraday low at 100.89 turned the structure into a double bottom. Alexion’s RS Rating was lackluster, but has improved.